Martin R Farlow
Articles
-
Nov 17, 2024 |
nature.com | Stephan A. Kaeser |Christian la Fougère |Jonathan Voglein |Johannes Levin |Nick Fox |Henrik Zetterberg | +16 more
AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.
-
Nov 17, 2024 |
AbstractDisease-modifying therapies for Alzheimer’s disease (AD) are likely to be most beneficial when initiated in the presymptomatic phase. To track the benefit of such interventions, fluid biomarkers are of great importance, with neurofilament light chain protein (NfL) showing promise for monitoring neurodegeneration and predicting cognitive outcomes.
-
Sep 20, 2024 |
nature.com | Shannon L. Risacher |Paula J Bice |Jared Brosch |Kelley Faber |Martin R Farlow |Tatiana Foroud | +29 more
AbstractDetermining the genetic architecture of Alzheimer’s disease pathologies can enhance mechanistic understanding and inform precision medicine strategies. Here, we perform a genome-wide association study of cortical tau quantified by positron emission tomography in 3046 participants from 12 independent studies. The CYP1B1-RMDN2 locus is associated with tau deposition.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →